Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Colorectal Neoplasms × Valproic Acid × Clear all

Phase

Phase 2 3 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 4 Myelodysplastic Syndromes 2 Recurrence 1 Neoplasm Metastasis 1 Melanoma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Leukemia 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cetuximab 39 Irinotecan 32 pembrolizumab 31 Capecitabine 31 Oxaliplatin 30 Bevacizumab 29 Fluorouracil 27 Leucovorin 26 Nivolumab 17 Gemcitabine 13 Cyclophosphamide 12 regorafenib 10 Folfox protocol 10 Cisplatin 10 Pemetrexed 9 Carboplatin 9 Paclitaxel 8 IFL protocol 8 tislelizumab 7 Panitumumab 7 130-nm albumin-bound paclitaxel 7 durvalumab 6 HMPL-013 6 Drug Therapy 6 irinotecan sucrosofate 5 Trifluridine 5 Specimen Handling 5 Ipilimumab 5 Interleukin-2 5 Docetaxel 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01898104 2023-03-24

V-shoRT-R3

National Cancer Institute, Naples

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡